{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:12Z","timestamp":1792161072329,"version":"4.4.0"},"reference-count":14,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"2","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Knowledge about fundamental sleep disorders and dysregulation that occurs in children with PTSD is limited. Prazosin is an alpha-1 receptor antagonist often used off label for the treatment of PTSD-associated nightmares in adults; however, evaluation of its use in pediatrics and adolescents is limited. The primary objective of this study was to assess the impact of prazosin on nightmares associated with PTSD in this population. Secondary objectives included assessing side effects, changes in blood pressure, and 30-day readmission rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, single-center chart review of inpatients diagnosed with PTSD nightmares from January 1, 2017, to July 31, 2019. Patients 4 to 18 years old with a PTSD diagnosis, experiencing nightmares, and initiating any dose of prazosin were assessed to determine efficacy and tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-two patients were evaluated to determine symptom improvement after initiation of prazosin for PTSD nightmares in children and adolescents. Of the 42 patients, 24 (57.1%) reported improvement in nightmares (average dose 1.05 mg). For secondary results, 38 (90.5%) patients continued prazosin at discharge, and 2 (5%) were readmitted within 30 days for reasons other than PTSD-associated nightmares. Thirty-four (81%) reported having no adverse effects to prazosin. There was no significant difference in systolic (P\u2009=\u2009.1883) or diastolic (P\u2009=\u2009.2777) blood pressure preinitiation and postinitiation of prazosin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite the limitations of this retrospective study, the data suggests that prazosin may be associated with an improvement in nightmares in children and adolescents with PTSD. Adverse events were rarely reported, and there was no significant change in blood pressure with initiation of prazosin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.9740\/mhc.2021.03.045","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:00:07Z","timestamp":1617184807000},"page":"45-49","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents"],"prefix":"10.9740","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9628-0857","authenticated-orcid":true,"given":"Nancy","family":"Hudson","sequence":"first","affiliation":[{"name":"(Corresponding author) PGY-1 Pharmacy Practice Resident, The University of Kansas Health System, Kansas City, Kansas, nhk99@mail.umkc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8893-4171","authenticated-orcid":true,"given":"Steven","family":"Burghart","sequence":"additional","affiliation":[{"name":"Clinical Pharmacist, The University of Kansas Health System, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-8419","authenticated-orcid":true,"given":"Jill","family":"Reynoldson","sequence":"additional","affiliation":[{"name":"Pharmacy Manager, Psychiatry, The University of Kansas Health System, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-0101","authenticated-orcid":true,"given":"Dennis","family":"Grauer","sequence":"additional","affiliation":[{"name":"Associate Professor, Vice Chair of Research, The University of Kansas School of Pharmacy, Lawrence, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2021033113592355500_i2168-9709-11-2-45-b01","doi-asserted-by":"crossref","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593- 602. DOI: 10.1001\/archpsyc.62.6.593. PubMed PMID: 15939837.","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"2021033113592355500_i2168-9709-11-2-45-b02","doi-asserted-by":"crossref","unstructured":"Neylan TC, Marmar CR, Metzler TJ, Weiss DS, Zatzick DF, Delucchi KL, et al. Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry. 1998; 155(7): 929- 33. DOI: 10.1176\/ajp.155.7.929. PubMed PMID: 9659859.","DOI":"10.1176\/ajp.155.7.929"},{"key":"2021033113592355500_i2168-9709-11-2-45-b03","doi-asserted-by":"crossref","unstructured":"Woodward SH, Arsenault NJ, Murray C, Bliwise DL. Laboratory sleep correlates of nightmare complaint in PTSD inpatients. Biol Psychiatry. 2000; 48(11): 1081- 7. DOI: 10.1016\/s0006-3223(00)00917-3. PubMed PMID: 11094141.","DOI":"10.1016\/S0006-3223(00)00917-3"},{"key":"2021033113592355500_i2168-9709-11-2-45-b04","doi-asserted-by":"crossref","unstructured":"Kovachy B, O'Hara R, Hawkins N, Gershon A, Primeau MM, Madej J, et al. Sleep disturbance in pediatric PTSD: current findings and future directions. J Clin Sleep Med. 2013; 9(5): 501- 10. DOI: 10.5664\/jcsm.2678. PubMed PMID: 23674943; PubMed Central PMCID: PMC3629326.","DOI":"10.5664\/jcsm.2678"},{"key":"2021033113592355500_i2168-9709-11-2-45-b05","unstructured":"National Institute of Mental Health [Internet]. Post-traumatic stress disorder; 2019[cited 2019 Dec 1].NIMH Strategic Plan for Research.Available from: https:\/\/www.nimh.nih.gov\/health\/topics\/post-traumatic-stress-disorder-ptsd\/index.shtml"},{"key":"2021033113592355500_i2168-9709-11-2-45-b06","doi-asserted-by":"crossref","unstructured":"Cohen JA, Mannarino AP, Perel JM, Staron V. A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): 811- 9. DOI: 10.1097\/chi.0b013e3180547105. PubMed PMID: 17581445.","DOI":"10.1097\/chi.0b013e3180547105"},{"key":"2021033113592355500_i2168-9709-11-2-45-b07","doi-asserted-by":"crossref","unstructured":"Geracioti TD Jr, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001; 158(8): 1227- 30. DOI: 10.1176\/appi.ajp.158.8.1227. PubMed PMID: 11481155.","DOI":"10.1176\/appi.ajp.158.8.1227"},{"key":"2021033113592355500_i2168-9709-11-2-45-b08","doi-asserted-by":"crossref","unstructured":"Boehnlein JK, Kinzie JD. Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J Psychiatr Pract. 2007; 13(2): 72- 8. DOI: 10.1097\/01.pra.0000265763.79753.c1. PubMed PMID: 17414682.","DOI":"10.1097\/01.pra.0000265763.79753.c1"},{"key":"2021033113592355500_i2168-9709-11-2-45-b09","doi-asserted-by":"crossref","unstructured":"Aurora RN, Zak RS, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, et al. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med. 2010; 6(4): 389- 401. PubMed PMID: 20726290.","DOI":"10.5664\/jcsm.27883"},{"key":"2021033113592355500_i2168-9709-11-2-45-b10","doi-asserted-by":"crossref","unstructured":"Morgenthaler TI, Auerbach S, Casey KR, Kristo D, Maganti R, Ramar K, et al. Position paper for the treatment of nightmare disorder in adults: an American Academy of Sleep Medicine position paper. J Clin Sleep Med. 2018; 14(6): 1041- 55. DOI: 10.5664\/jcsm.7178. PubMed PMID: 29852917; PubMed Central PMCID: PMC5991964.","DOI":"10.5664\/jcsm.7178"},{"key":"2021033113592355500_i2168-9709-11-2-45-b11","doi-asserted-by":"crossref","unstructured":"Akinsanya A, Marwaha R, Tampi RR. Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares. J Clin Psychopharmacol. 2017; 37(1): 84- 8. DOI: 10.1097\/JCP.0000000000000638. PubMed PMID: 27930498.","DOI":"10.1097\/JCP.0000000000000638"},{"key":"2021033113592355500_i2168-9709-11-2-45-b12","doi-asserted-by":"crossref","unstructured":"Keeshin BR, Ding Q, Presson AP, Berkowitz SJ, Strawn JR. Use of prazosin for pediatric PTSD-associated nightmares and sleep disturbances: a retrospective chart review. Neurol Ther. 2017; 6(2): 247- 57. DOI: 10.1007\/s40120-017-0078-4. PubMed PMID: 28755207; PubMed Central PMCID: PMC5700900.","DOI":"10.1007\/s40120-017-0078-4"},{"key":"2021033113592355500_i2168-9709-11-2-45-b13","doi-asserted-by":"crossref","unstructured":"Harpaz-Rotem I, Rosenheck RA. Tracing the flow of knowledge. Arch Gen Psychiatry. 2009; 66(4): 417- 21. DOI: 10.1001\/archgenpsychiatry.2008.536. PubMed PMID: 19349311.","DOI":"10.1001\/archgenpsychiatry.2008.536"},{"key":"2021033113592355500_i2168-9709-11-2-45-b14","unstructured":"Prazosin hydrochloride [package insert]. New York: Pfizer Labs; 2009."}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/2\/45\/2800661\/i2168-9709-11-2-45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/2\/45\/2800661\/i2168-9709-11-2-45.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:18:43Z","timestamp":1731669523000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/11\/2\/article-p45.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2021.03.045","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}